1 一、本次股份解除质押的相关情况 证券代码：600998 证券简称：九州通 公告编号：临 2025-042 九州通医药集团股份有限公司 关于股东解除股份质押及质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●公司股东上海弘康办理完成72,240,000股的股份解除质押手续，本次解除质押股份 占其所持股份的比例为6.64%，占公司总股本的比例为1.43%。另外，公司股东上海弘康 办理完成88,010,000股的股份质押手续，本次质押股份占其所持股份的比例为8.09%，占 公司总股本的比例为1.75%。 ●公司股东上海弘康持有公司股份1,088,326,782股，占公司总股本的比例为21.58%。 本次股份解除质押及质押办理完成后，上海弘康累计质押公司股份533,461,892股，占其 所持股份的比例为49.02%，占公司总股本的比例为10.58%。 ●截至2025年6月6日，控股股东楚昌投资及其一致行动人合计持有公司股份 2,316,462,501股，占公司总股本的比例为45.94%。本次股份解除质 ...

Core Viewpoint - 九州通 is undergoing a strategic transformation towards light asset operations and aims to become a dual-listed company on A-shares and public REITs, enhancing its market position in the biopharmaceutical industry [1][2]. Group 1: Strategic Transformation - 九州通 is focusing on a "three new and two modernization" strategy in 2024, achieving significant results in new products, new retail, new medical services, digitalization, and real estate securitization [2]. - The company has established a multi-level real estate equity capital operation platform, marking its transition from heavy assets to light assets [3]. Group 2: Financial Performance - In 2024, 九州通's total revenue reached 151.81 billion yuan, a year-on-year increase of 2.58%, while net profit attributable to shareholders was 2.507 billion yuan, up 39.88% [2]. - In Q1 2025, the company reported revenue of 42.016 billion yuan, a 3.82% increase year-on-year, and a net profit of approximately 970 million yuan, reflecting an 80.38% growth [2]. Group 3: Product Pipeline Expansion - 九州通's product pipeline is expanding with the approval of "Betamethasone Sodium Phosphate Injection," which is expected to enhance market share and strengthen the company's competitive position in the injection product market [1][4]. - The company achieved sales revenue of 3.007 billion yuan from its self-produced and OEM pharmaceutical business in 2024, marking a 21.49% increase [5]. Group 4: Research and Development - 九州通's R&D investment in 2024 was 346 million yuan, reflecting a year-on-year growth of 24.32% [2].

证券代码：600998 证券简称：九州通 公告编号：临 2025-040 九州通医药集团股份有限公司 关于参加湖北辖区上市公司 2025 年投资者 网上集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 为进一步加强与投资者的互动交流，九州通医药集团股份有限公司（以下简 称"公司"）将参加由湖北证监局、湖北省上市公司协会与深圳市全景网络有限 公司联合举办的"2025 年湖北辖区上市公司投资者集体接待日活动"，现将相关 事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号（全景财经），或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 6 月 12 日（周四）14:00-16:40。届时公司 高管将在线就公司经营成果、业绩亮点、权益分派、ESG 实践及"三新两化"战略 实施情况等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃 参与！ 特此公告。 九州通医药集团股份有限公司董事会 2025 年 6 ...

证券代码：600998 证券简称：九州通 公告编号：临 2025-041 九州通医药集团股份有限公司 关于倍他米松磷酸钠注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 6 月 4 日，九州通医药集团股份有限公司（以下简称"公司"或"九 州通"）全资子公司北京京丰制药集团有限公司（以下简称"京丰制药"）的下 属公司汇禹远和（海南）药业有限公司（以下简称"汇禹远和"）收到国家药品 监督管理局核准签发的倍他米松磷酸钠注射液《药品注册证书》。现将相关情况 公告如下： 一、药品注册证书主要信息 药品名称：倍他米松磷酸钠注射液 剂型：注射剂 申请事项：药品注册（境内生产） 规格：1ml:4mg（按 C₂₂H₂₉FO₅计） 注册分类：化学药品 3 类 证书编号：2025S01482 药品批准文号：国药准字 H20254262 药品批准文号有效期：至 2030 年 5 月 26 日 上市许可持有人：汇禹远和（海南）药业有限公司 药品生产企业：津药和平（天津）制药有限公司 审批结论：根据《中华人民共和 ...

Core Insights - The AMAC Wholesale Retail Trade Index (AMAC批零, H11045) increased by 1.3%, closing at 1617.5 points with a trading volume of 31.254 billion [1] - Over the past month, the index has risen by 2.93%, by 1.85% over the last three months, and by 0.73% year-to-date [1] Index Composition - The AMAC Wholesale Retail Trade Index is based on 43 industry classification indices, excluding manufacturing, and is compiled according to the classification guidelines from the China Securities Association [1] - The top ten weighted stocks in the index are: Huadong Medicine (5.33%), Yonghui Supermarket (3.05%), Digital China (2.87%), Shanghai Pharmaceuticals (2.83%), Wancheng Group (2.26%), Wuchan Zhongda (2.21%), Yifeng Pharmacy (2.19%), Jiuzhoutong (1.83%), Sinopharm (1.58%), and Kidswant (1.57%) [1] Market Distribution - The market distribution of the AMAC Wholesale Retail Trade Index shows that the Shenzhen Stock Exchange accounts for 53.12%, while the Shanghai Stock Exchange accounts for 46.88% [1] Industry Breakdown - In terms of industry composition, discretionary consumption accounts for 36.90%, healthcare for 31.52%, industrials for 22.28%, staples for 4.58%, energy for 2.78%, real estate for 1.27%, and financials for 0.67% [2]

Core Viewpoint - The China Securities Index for Food and Major Consumer Goods Retail has shown a decline in performance over various time frames, indicating potential challenges in the sector [1][2]. Group 1: Index Performance - The China Securities Index for Food and Major Consumer Goods Retail is currently at 9719.75 points, having decreased by 0.13% over the past month, 2.88% over the past three months, and 4.47% year-to-date [1]. - The index is based on a sample of listed companies in the food and drug retail sector, reflecting the overall performance of these securities [1]. Group 2: Index Composition - The top ten weighted companies in the index include Yonghui Supermarket (6.96%), Digital China (6.48%), Shanghai Pharmaceuticals (6.14%), Yifeng Pharmacy (4.97%), and others, indicating a concentration in a few key players [1]. - The index is primarily composed of companies listed on the Shanghai Stock Exchange (55.91%) and Shenzhen Stock Exchange (44.09%) [1]. Group 3: Industry Breakdown - The industry composition of the index shows that pharmaceutical commerce accounts for 48.65%, specialized retail for 19.84%, department stores for 16.99%, and supermarkets and convenience stores for 14.52% [2]. - The index samples are adjusted biannually, with changes implemented on the next trading day following the second Friday of June and December [2].

证券代码：600998 证券简称：九州通 公告编号：临 2025-038 九州通医药集团股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 根据《公司法》《上市公司章程指引》等法律法规、规范性文件及《公司章程》的相关规定，九州通医 药集团股份有限公司（以下简称"公司"）董事会增加职工代表董事1名，由职工代表大会选举产生。 为完善公司治理结构，公司已于2025年5月22日召开第五届职工代表大会第一次会议，选举吴志龙先生 （简历附后）为公司第六届董事会职工代表董事。吴志龙先生将与公司现任非职工代表董事共同组成公 司第六届董事会，任期自本次职工代表大会决议通过之日起至公司第六届董事会届满之日止。 经核查，吴志龙先生的任职资格和条件符合《公司法》《公司章程》和其他相关法规关于公司职工代表 董事任职的规定。吴志龙先生当选后，公司第六届董事会成员中兼任公司高级管理人员以及由职工代表 担任的董事人数总计不超过公司董事总数的二分之一，符合相关法律法规及《公司章程》的规定。 特此公告。 九州通医药集团股份有 ...

Core Viewpoint - The pharmaceutical distribution industry is facing significant challenges, including a wave of pharmacy closures, but Jiuzhoutong is adapting by expanding its business model and focusing on new markets [2][5]. Company Overview - Jiuzhoutong, a leading pharmaceutical distribution company, held its 2024 annual shareholder meeting on May 23, 2023, in Wuhan, attracting several small shareholders [2]. - The company operates primarily through a franchise model for its pharmacies, which minimizes the impact of individual pharmacy profitability on the overall company [3][6]. Financial Performance - For 2024, Jiuzhoutong expects a 15.33% year-on-year increase in net profit to 2.507 billion yuan, while revenue is projected to rise only slightly by 1.11% [3]. - The company reported a significant growth in its medical aesthetics business, achieving sales revenue of 851 million yuan, a 120.47% increase year-on-year, with a compound annual growth rate of 111.64% from 2022 to 2024 [9]. Market Challenges - The pharmaceutical industry is experiencing unprecedented challenges, including a decline in the number of retail pharmacies, with closures reaching 14,114 in the fourth quarter of 2024 [5]. - Despite these challenges, Jiuzhoutong plans to increase its pharmacy count to over 33,500 by the end of the year, with a current total of 29,331 stores [5][6]. Strategic Initiatives - Jiuzhoutong is focusing on expanding its presence in the medical device sector and targeting lower-tier markets through acquisitions of local pharmaceutical distribution companies [9]. - The company has recently participated in the restructuring of *ST Meigu, investing 673 million yuan to acquire shares, which aligns with its medical aesthetics business [7][9]. Accounts Receivable Management - Jiuzhoutong faces challenges with accounts receivable, with values reported at 27.576 billion yuan, 24.72 billion yuan, and 29.477 billion yuan for the years ending 2022, 2023, and 2024, respectively [9]. - The company manages credit and collection through a dedicated credit management department, ensuring stable cash flow from large public hospitals [9].

Group 1 - The company held its 2024 annual shareholders' meeting on May 23, 2025, at its headquarters in Wuhan, with the meeting chaired by Chairman Liu Changyun [2][3] - The meeting's agenda and procedures were in accordance with relevant laws, regulations, and the company's articles of association [3][4] - A total of 3,282,815,074 shares were represented at the meeting, accounting for 65.8349% of the total voting shares [3] Group 2 - 29 shareholders and their proxies attended the meeting in person, representing 2,701,993,476 shares, or 54.1869% of the total voting shares [3] - 419 shareholders participated in the online voting, representing 14,180,000 shares, or 79.2179% of the preferred shares [3] - All proposed resolutions were approved during the meeting, including a special resolution for one of the agenda items [4]

证券代码：600998 证券简称：九州通 公告编号：临 2025-038 九州通医药集团股份有限公司 关于选举职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《公司法》《上市公司章程指引》等法律法规、规范性文件及《公司 章程》的相关规定，九州通医药集团股份有限公司（以下简称"公司"）董事 会增加职工代表董事 1 名，由职工代表大会选举产生。 为完善公司治理结构，公司已于 2025 年 5 月 22 日召开第五届职工代表大 会第一次会议，选举吴志龙先生（简历附后）为公司第六届董事会职工代表董 事。吴志龙先生将与公司现任非职工代表董事共同组成公司第六届董事会，任 期自本次职工代表大会决议通过之日起至公司第六届董事会届满之日止。 经核查，吴志龙先生的任职资格和条件符合《公司法》《公司章程》和其 他相关法规关于公司职工代表董事任职的规定。吴志龙先生当选后，公司第六 届董事会成员中兼任公司高级管理人员以及由职工代表担任的董事人数总计不 超过公司董事总数的二分之一，符合相关法律法规及《公司章程》的规定。 特此公告。 ...